STERIS plc posted a sharp 4.5% single-session gain on May 12 — its fiscal Q4 earnings day — yet the stock remains nearly 1% lower on the week and down 17% year-to-date. The tension between a solid earnings beat and a market that refuses to re-rate the shares higher defines the setup heading into the new fiscal year.
The most immediate Street signal came from Keybanc on May 13. Analyst Brett Fishbin kept his Overweight rating intact but cut his price target from $291 to $269 — a 7.6% reduction even in the wake of a headline earnings beat. That move captures the broader analyst tone. Across the coverage universe, the consensus remains a "buy" with a mean target near $257, implying roughly 22% upside to the current $210.85 close. Yet targets have been drifting lower, not higher. The gap between where analysts thought the stock should trade six months ago and where they think it should trade now has narrowed meaningfully. Bulls point to the fiscal Q4 results: 5% organic revenue growth, EBIT margins expanding 110 basis points year-over-year, and EPS of $2.74 — up 14% from the prior year, aided by the divestiture of the dental segment. Bears counter with capital equipment sales falling roughly 16% year-over-year and the equipment backlog shrinking by $66 million in the quarter, raising questions about the next leg of growth.
Short interest is not the dominant story here, but it has moved in a way worth noting. Estimated short interest jumped 21% in the past week to around 1.9% of the free float — still a modest level in absolute terms, but the pace of that rebuild is the noteworthy detail. Through late April and early May, short interest had been running below 1.6% and grinding lower. The step-change higher into the earnings print suggests some traders were adding protection rather than outright conviction. Borrow conditions remain relaxed: cost to borrow ticked up about 50% on the week but is still just 0.50%, and the lending market availability is well above tight territory. The ORTEX short score is at 31.8, in the lower half of its range, with no sign of a crowded short-side trade forming.
Options positioning has shifted from cautious to relatively neutral in one session. The put/call ratio dropped to 1.08 on May 12 from 1.31 the day before — well below its 20-day average of 1.27 and approximately 0.8 standard deviations below that mean. The whole options picture has been schizophrenic this year: the PCR ran as low as 0.15 in mid-April, spiked above 1.79 on April 20, and has now settled back into a more muted zone. The post-earnings one-day move of +1.6% was modest by historical context, consistent with the prior fiscal Q3 result where the stock barely budged.
Valuation offers limited comfort. The trailing P/E is around 18x on the snapshot data, and EV/EBITDA has eased modestly over the past month but remains at roughly 12x — a reasonable multiple for the sector but not cheap enough to serve as a floor with earnings growth questions circling the capital equipment segment. The dividend score ranks in the 97th percentile of the universe, reflecting the company's long dividend growth track record, though the dividend history in the data only runs through mid-2022 and is stale. The forward yield is approximately 1.3%. Wellington Management added a notable 1.47 million shares in the most recent quarter — the biggest move among the top institutional holders — while BlackRock and State Street also added modestly. That institutional buying provides some structural support beneath the price.
With the next earnings event not yet scheduled and the capital equipment backlog the clearest near-term watch item, the quarter-by-quarter trajectory of that segment is where the stock's re-rating argument will either rebuild or stall.
See the live data behind this article on ORTEX.
Open STE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
